Short- and Long-term Risks of Highly Active Antiretroviral Treatment with Incident Opportunistic Infections among People Living with HIV/AIDS.
AIDS-Related Opportunistic Infections
/ diagnosis
Acquired Immunodeficiency Syndrome
/ complications
Adolescent
Adult
Aged
Anti-Retroviral Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
/ adverse effects
Comorbidity
Female
HIV Infections
/ complications
Humans
Incidence
Male
Middle Aged
Risk Assessment
Risk Factors
Socioeconomic Factors
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 03 2019
05 03 2019
Historique:
received:
10
07
2018
accepted:
06
12
2018
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
25
9
2020
Statut:
epublish
Résumé
Highly active antiretroviral therapy (HAART) causes a rapid increase of CD4 + T cells counts during the first 3-6 months of treatment and may enhance the development of opportunistic infections (OIs). However, the short- and long-term effects of HAART exposure on the development of incident OIs has not been extensively studied. This nationwide longitudinal study followed up a total of 26,258 people living with HIV/AIDS (PLWHA) to ascertain the short- and long-term effects of HAART on incident OIs. During 150,196 person-years of follow-up, 6,413 (24.4%) PLWHA had new onset of OIs. After adjusting for demographics, comorbidities, and AIDS status, PLWHA who received HAART were more likely to develop OIs than those who did not receive HAART. Considering the short- and long-term effects of HAART on the development of OIs, HAART was found to be a risk factor for developing OIs during the first 90 days of treatment, but a protective factor against OIs after 180 days of HAART use. The risk for the development of active OIs significantly decreased as the duration of HAART increased (P < 0.001). Our study suggests that HAART is a risk factor for developing OIs in the short term, but is a protective factor in the long term.
Identifiants
pubmed: 30837537
doi: 10.1038/s41598-019-39665-6
pii: 10.1038/s41598-019-39665-6
pmc: PMC6400900
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3476Références
J Clin Epidemiol. 2006 Oct;59(10):1110-4
pubmed: 16980152
J Neurovirol. 2010 Mar;16(2):179-84
pubmed: 20370600
Infect Dis Clin North Am. 2014 Sep;28(3):501-18
pubmed: 25151568
Int J Infect Dis. 2009 Jan;13(1):e1-8
pubmed: 18602329
J Infect. 2007 Nov;55(5):464-9
pubmed: 17714788
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):572-8
pubmed: 27049511
AIDS. 2005 Jul 22;19(11):1201-6
pubmed: 15990574
Clin Infect Dis. 2005 May 15;40(10):1500-7
pubmed: 15844073
Clin Infect Dis. 2005 Dec 15;41(12):1772-82
pubmed: 16288403
J Infect Dis. 1999 Oct;180(4):1050-6
pubmed: 10479130
MMWR Recomm Rep. 2008 Dec 5;57(RR-10):1-12
pubmed: 19052530
J Clin Psychiatry. 2015 Apr;76(4):e505-11
pubmed: 25919843
AIDS. 2007 Nov 30;21(18):2534-6
pubmed: 18025892
Immunol Rev. 2013 Jul;254(1):54-64
pubmed: 23772614
Lancet. 2007 Feb 24;369(9562):623-5
pubmed: 17321295
AIDS. 2014 Oct 23;28(16):2461-73
pubmed: 25265230
J Infect Dis. 2015 Nov 1;212(9):1366-75
pubmed: 26044289
JAMA. 2001 Apr 4;285(13):1736-45
pubmed: 11277828